Business
-
A newly formed company called Murano Bidco, which is controlled by the Carlyle Group, has agreed to pay approximately £958 million to acquire inhalation CDMO Vectura, the companies have announced. According to the announcement, Bidco… Read more . . .
-
Innoviva is buying back GlaxoSmithKline’s entire stake in the company, a total of 32 million shares (~ 32% of company). Innoviva (formerly Theravance, Inc.), was spun off from Theravance in 2013 to manage the royalties… Read more . . .
-
Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3… Read more . . .
-
Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone’s etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing… Read more . . .
-
Swiss start-up Akroswiss has announced that it raised “several million Swiss Franc” for development of the company’s midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include… Read more . . .
-
DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for… Read more . . .
-
A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900).… Read more . . .
-
Inhalation CDMO Vectura has signed an agreement with Inspira Pharmaceuticals to develop an inhaled formulation of a plant extract Inspira is developing for the treatment of COVID-19, the company said. Vectura will create a version of… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of Ryaltris-AZ mometasone furoate / azelastine nasal spray for the treatment of allergic rhinitis in India, touting the low cost of the nasal spray compared to similar products. According to… Read more . . .
-
Hikma Pharmaceuticals said that the FDA has approved an amendment to the company’s ANDA for its generic version of Advair Diskus fluticasone propionate / salmeterol DPI, and the company has subsequently restarted the launch of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland